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Edited by Laszlo NagyAbstract 12-Phenylacetyl-ricinoleoyl-vanillamide (phenylace-
tylrinvanil, PhAR, IDN5890), is an ultra-potent agonist of
human vanilloid TRPV1 receptors also endowed with moderate
aﬃnity for human cannabinoid CB2 receptors. To improve its
CB2 aﬃnity and temper its potency at TRPV1, the modiﬁcation
of the polar headgroup and the lipophilic 12-acylgroup of PhAR
was pursued. Replacement of the vanillyl headgroup of PhAR
with various aromatic or alkyl amino groups decreased activity
at TRPV1 receptors, although the dopamine, cyclopropylamine,
1 0-(R)- and 1 0-(S)-methyl-ethanolamine, and ethanolamine deriv-
atives retained signiﬁcant potency (EC50 31–126 nM). Within
these compounds, the 12-phenylacetylricinoleyl cyclopropyla-
mide and ethanolamide were the strongest ligands at CB2 recep-
tors, with Ki of 22 and 44 nM, and 14- and >20-fold selectivity
over cannabinoid CB1 receptors, respectively. The propyl- and
allyl-derivatives also exhibited high aﬃnity at CB2 receptors
(Ki = 40 and 22 nM, with 40 and >80-fold selectivity over CB1
receptors, respectively), but no activity at TRPV1 receptors.
The cyclopropyl- and allyl-derivatives behaved as CB2 inverse
agonists in the GTP-c-S binding assay. Addition of para-meth-
oxy, -tert-butyl or -chlorine groups to the 12-phenylacetyl moi-
ety of PhAR produced compounds that retained full potency at
TRPV1 receptors, but with improved selectivity over CB2 or
CB1 receptors. Thus, the manipulation of PhAR led to the devel-
opment of the ﬁrst CB2/TRPV1 dual ligands and of an entirely
new class of inverse agonists at CB2 receptors. Both types of
compounds might ﬁnd application in the treatment of inﬂamma-
tion, and represent new molecular probes to investigate the endo-
cannabinoid–endovanilloid signalling system.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Recent studies have highlighted the importance of ‘‘multi-
ple-target’’ therapies for the treatment of chronic and inﬂam-
matory pain and migraine [1–4]. Surprisingly, while drugs
with a pleiotropic mechanism of action are under develop-
ment as anti-tumor agents [5], the therapeutic potential of
compounds with more than one target in nociception is still
largely unexplored. Over the past few years, two types of
receptors have gained growing relevance as molecular targets
for the discovery of new analgesic and anti-inﬂammatory
drugs, namely the cannabinoid receptors subtype 1 and 2
(CB1 and CB2), and the transient receptor potential channels
of type V1 (TRPV1, also known as vanilloid VR1 receptors).
These receptors were identiﬁed in the course of studies of the
molecular mode of action of two plant natural products, the
psychotropic principle of Cannabis, ()-D9-tetrahydrocannab-
inol, and the pungent component of hot chilli peppers, capsa-
icin [6–8]. An opposing role for CB1/CB2 and TRPV1
receptors in the tonic control of nociception and as molecular
transducers of inﬂammatory and thermal pain, respectively,
has been demonstrated (see [9,10] for reviews). Accordingly,
agonists of both cannabinoid receptor subtypes (see [9] for re-
view), as well as agonists and antagonists of TRPV1 channels
produce strong antinociceptive eﬀects in animal models of
chronic, neuropathic and inﬂammatory pain (see [10] for re-
view). In particular, the analgesic and anti-inﬂammatory ef-
fects of TRPV1 agonists appear to be paradoxical as
TRPV1 receptors are coupled to the release of pro-algesic
and pro-inﬂammatory mediators from sensory neuron eﬀer-
ents. However, TRPV1 is immediately desensitized after its
activation by agonists, thus rendering these neurons refrac-
tory to further stimulation, with subsequent analgesic and
anti-inﬂammatory eﬀects being observed after a ﬁrst pro-noci-
ceptive response to the agents [10]. Also ‘‘indirect’’ agonists of
cannabinoid receptors, i.e. inhibitors of endogenous cannabi-
noid (endocannabinoid) inactivation, have been suggested as
possible leads for the development of analgesic drugs
[11,12]. Finally, recent evidence also points to cannabinoid
CB2 receptor antagonists/inverse agonists as promising anti-
inﬂammatory agents [13,14].blished by Elsevier B.V. All rights reserved.
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inﬂammatory agents, once assumed to function via a single
mechanism of action, can instead interact with several molec-
ular targets. Thus, it was shown that some cyclooxygenase
inhibitors also inhibit endocannabinoid hydrolysis via the
fatty acid amide hydrolase (FAAH) [12,15], or bind with mod-
erate aﬃnity to cannabinoid CB2 receptors [15]. Furthermore,
acetaminophen, possibly the most popular analgesic drug,
may act in vivo partly through its conversion into AM404
[16], a compound that inhibits endocannabinoid cellular reup-
take and activates/desensitizes TRPV1 receptors [17–19]. We
have previously shown that ‘‘hybrid’’ agonists of CB1 and
TRPV1 receptors, like arvanil [20–23] and O-1861 [24], pro-
duce stronger analgesic actions than those observed with
‘‘pure’’ agonists with the same aﬃnity for each receptor type.
In particular, arvanil inhibits both the ﬁrst and, particularly,
the second phase of formalin-induced nocifensive behaviour
[23], as well as visceral nociception in the mouse p-phenylqui-
none test [25]. Despite: (1) these promising results with CB1/
TRPV1 ‘‘hybrid’’ ligands; (2) the well-established role of
CB2 receptors in inﬂammatory and neuropathic conditions
[26,27]; and (3) the growing evidence that some COX inhibi-
tors may act in part via CB2 or TRPV1 receptors [12,15], no
CB2/TRPV1 ‘‘hybrid’’ ligand has been developed to date.
We recently reported that phenylacetylrinvanil (PhAR,
IDN5890), a compound obtained by implanting a structural
element of resiniferatoxin (RTX) on the capsaicinoid olvanil,
is a very potent and eﬃcacious agonist of human vanilloid
TRPV1 receptors, with moderate aﬃnity for human cannabi-
noid CB2 receptors (Fig. 1) [28]. To temper its strong potency
at TRPV1, a property that is useful to treat bladder hyper-
reactivity but may cause undesirable side eﬀects in vivo, and
to improve its aﬃnity for CB2, we have modiﬁed here the po-
lar headgroup of phenylacetylrinvanil and its lipophilic 12-acyl
moiety, obtaining not only the ﬁrst class of ‘‘hybrid’’ dual li-
gands of CB2 and TRPV1 receptors, but also the ﬁrst exam-
ples of fatty-acid derived selective CB2 ligands lacking
polyunsaturation. Both types of compounds are of potential
interest for the treatment of inﬂammation, and represent
new molecular probes to investigate the endocannabinoid–
endovanilloid system.2. Materials and methods
2.1. Synthesis and characterization of compounds
12-Acyl derivatives of ricinoleic acid were obtained by esteriﬁcation
of the trichloroethyl ester of ricinoleic acid with the suitable acid and
deprotection, and their amidation was carried out with the PPAA-
TEA protocol [29] (Fig. 1). All end products (Table 1) were thoroughly
characterized spectroscopically (1H- and 13C NMR, IR, HR-MS).2.2. Binding assays for aﬃnity at human recombinant cannabinoid
receptors
For CB1 and CB2 receptor binding assays, the new compounds were
analyzed by using P2 membranes from COS cells transfected stably
with either the human CB1 or CB2 receptor and [
3H]-()-cis-3-
[2-hydroxy-4-(1,1-dimethylheptyl)-phenyl]-trans-4-(3-hydroxy-propyl)-
cyclohexanol ([3H]CP-55,940) as the high-aﬃnity ligand as described
by the manufacturer’s instructions (Perkin Elmer, Italia). Displace-
ment curves were generated by incubating drugs with 0.5 nM of
[3H]CP-55,940. In all cases, Ki values were calculated by applying
the Cheng–Prusoﬀ equation to the IC50 values (obtained by Graph-
Pad) for the displacement of the bound radioligand by increasing con-
centrations of the test compounds.2.3. GTP-c-S binding assays
These assays were performed as previously described [30], using
CHO cells stably overexpressing the human recombinant CB2 receptor
(10 lg/ml protein), 0.7 nM [35S]GTP-c-S and 320 lMGDP, and a ﬁnal
assay volume of 250 ll.
2.4. Assays for activity at human recombinant TRPV1
Human embryonic kidney (HEK) 293 stably overexpressing recom-
binant human TRPV1 cDNA were grown as monolayers in minimum
essential medium supplemented with non-essential amino acids, 10%
fetal calf serum, and 0.2 mM glutamine, and maintained under 95%/
5%O2/CO2 at 37 C. The eﬀect of the substances on [Ca2+]I was deter-
mined by using Fluo-3, a selective intracellular ﬂuorescent probe for
Ca2+. One day prior to experiments, cells were transferred into six-well
dishes coated with Poly-L-lysine (Sigma) and grown in the culture med-
ium mentioned above. On the day of the experiment, the cells
(50–60000 per well) were loaded for 2 h at 25 C with 4 lM Fluo-3
methylester (Molecular probles) in DMSO. After the loading, cells
were washed with Tyrode pH = 7.4, trypsinized, resuspended in Tyr-
ode, and transferred into the cuvette of the ﬂuorescence detector (Per-
kin–Elmer LS50B) under continuous stirring. Experiments were
carried out by measuring cell ﬂuorescence at 25 C (kEX = 488 nm,
kEM = 540 nm) before and after the addition of the test compounds
at various concentrations. Potency data are expressed as the concentra-
tion exerting a half-maximal eﬀect (EC50), whereas the eﬃcacy of the
eﬀect was expressed as percent of the maximal observable eﬀect pro-
duced by ionomycin (4 lM) (Fig. 2).
Aﬃnity for TRPV1 was assessed by means of binding assays carried
out as described previously [20] with membranes from HEK cells sta-
bly overexpressing the human recombinant TRPV1, and using [3H]res-
iniferatoxin ([3H]RTX) as the high-aﬃnity ligand and RTX (1 lM) to
calculate speciﬁc binding (62 ± 5% of total binding).
2.5. Anandamide hydrolysis assays
The eﬀect of compounds on the enzymatic hydrolysis of
[14C]anandamide (6 lM) was studied by using membranes prepared
from rat brain incubated with increasing concentrations of compounds
in 50 mM Tris–HCl, pH 9, for 30 min at 37 C. These conditions are
optimal for FAAH, the enzyme that catalyzes the hydrolysis of both
anandamide and 2-arachidonoylglycerol. [14C]Ethanolamine produced
from [14C]anandamide hydrolysis was measured by scintillation count-
ing of the aqueous phase after extraction of the incubation mixture
with 2 volumes of CHCl3/CH3OH (2:1 by volume).3. Results
3.1. Activity of the novel compounds at human recombinant
cannabinoid CB1 and CB2 receptors
Table 1 shows the aﬃnity constants of the novel compounds
for human recombinant cannabinoid CB1 and CB2 receptors
as compared to the parent compound, PhAR. All compounds
with a non-phenolic headgroup exhibited higher aﬃnity at CB2
receptors than PhAR, while the serotonin, dopamine and tyra-
mine derivatives (compounds 4, 2 and 3, respectively) showed
only weak activity at both cannabinoid receptor types. All
compounds with signiﬁcant aﬃnity for CB2 were from 5- to
80-fold selective vs. CB1 receptors. The most potent CB2 li-
gands were the amides with ethanolamine (5), propylamine
(9), allylamine (10), cyclopropylamine (12) and 2 0-chloro-etha-
nolamine (13), with Ki values ranging between 22 and 44 nM.
Modiﬁcation of the 12-phenylacetyl moiety of PhAR led to
compounds with decreased aﬃnity for CB2 receptors, and, as
with PhAR, only very weak CB1 aﬃnity.
Two of the most potent ligands of CB2 receptors found here,
i.e. the allyl and cyclopropyl PhAR derivatives (compounds 10
and 12, respectively), behaved as inverse agonists in the GTP-
c-S binding assays (Fig. 3A and B). They inhibited [35S]GTP-c-





















Fig. 1. General synthetic scheme for the novel compounds reported here. Legend: i: ArCH2COOH, DCC, DMAP; ii: Zn, HOAc (overall 30–50%);
iii: PPAA, TEA, RNH2(20–70%) DCC = dicyclohexylcarbodiimide; PPAA = propylphosphonic acid anhydride; TEA = triethylamine.
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receptor, with potencies (59.1 and 12.8 nM, respectively) not
diﬀerent from their Ki values in CB2 binding assays (see Table
1). Compound 10 was less potent but more eﬃcacious than the
well established CB2 inverse agonist/antagonist SR144528,
whereas compound 12 was as potent and eﬃcacious as
SR144528 (Fig. 3C).
3.2. Activity of the novel compounds at human recombinant
vanilloid TRPV1 receptors
Table 1 and Fig. 2 show the EC50 values and the TRPV1-
mediated elevation by the novel compounds of intracellular
Ca2+ concentrations in HEK-293 overexpressing the human
recombinant TRPV1, as compared to the parent compound,
PhAR. The introduction of various substituents at the para-
position of the phenylacetyl moiety was tolerated, but replace-
ment of the vanillamine headgroup with other phenolic amines
as well as with various aliphatic aminoalcohols and aliphatic
amines caused, to a various extent, an overall decrease of activ-
ity. Thus, the three novel 12-acyl analogues of PhAR (com-
pounds 14–16) were as potent as, but less eﬃcacious than,
the parent compound, while the twelve compounds with a
non-vanillyl polar headgroup exhibited decreased TRPV1
potency. This decrease was less marked for the dopamide
(2), followed by the cyclopropylamide (12), 1 0-(R)- and 1 0-
(S)-methyl-ethanolamides (7 and 6), and ethanolamide (5)
derivatives (EC50 ranging between 31 and 126 nM). Remark-
ably, the ethanolamide (5) was also the most eﬃcacious non-
vanillyl TRPV1 agonist in the present study, whereas the other
non-vanillyl compounds exhibited a signiﬁcantly lower eﬃcacy
than PhAR and capsaicin [24]. No compound exerted any
eﬀect on [Ca2+]I in wild-type HEK-293 cells (not shown).
Finally, the two most eﬃcacious TRPV1 agonists (compounds
2 and 5) were also assayed in binding assays with [3H]RTX. In
agreement with previous studies with capsaicin, arvanil and
other fatty acid amide derivatives [20], the two compounds
exhibited Ki values signiﬁcantly higher than their EC50 values
in the Ca2+ assays (Table 1).
3.3. Activity of the novel compounds on anandamide hydrolysis
None of the 15 novel compounds exhibited any inhibitory
action against [14C]anandamide hydrolysis by rat brain mem-
branes up to a 50 lM concentration (data not shown).4. Discussion
We have reported here the discovery of the ﬁrst ‘‘hybrid’’
cannabinoid CB2 and vanilloid TRPV1 receptors ligands. We
had previously developed ‘‘hybrid’’ cannabinoid CB1/TRPV1
ligands, exempliﬁed by arvanil [20–23] and O-1861 [24]. When
given systemically, these compounds showed potent analgesic
properties, and arvanil was also found to counteract cancer
cell proliferation in vitro [21], neuronal excitotoxicity [31],spasticity in multiple sclerosis [23], and hyperkinesia in Hun-
tington’s disease [32] in vivo. On the other hand, because of
their partial agonist activity at CB1 receptors and their very
high potency at TRPV1 receptors, arvanil and O-1861 also ex-
ert profound central cannabimimetic actions (including hypo-
thermia, hypolocomotion and catalepsy [20,24,33]) when
administered systemically in rodents, and burning pain when
given topically [34]. These eﬀects might limit the therapeutic
use of these compounds, as well as of analogs showing a sim-
ilar pattern of TRPV1-CB1 activation. On the other hand,
compounds that at the same time behave as inverse agonists
at CB2 receptors and agonists at TRPV1 receptors, particu-
larly when not too potent as vanilloid agonists, are expected
to be devoid of most of the undesired eﬀects exhibited by arva-
nil and O-1816, and to maintain eﬃcacy as anti-inﬂammatory
agents. We have now identiﬁed two compounds endowed with
these pharmacological properties, both obtained by chemical
modiﬁcation of PhAR [28], a compound showing ultra-potent
activity at TRPV1 channels but weak aﬃnity at CB2 receptors.
It was previously shown that the acylation of arachidonic
acid with ethanolamine, propylamine, 1 0(R)-methyl-ethanol-
amine and, particularly, cyclopropylamine and 2 0-choloroeth-
anolamine result in ligands with high aﬃnity for CB1
receptors and 10 to 2000-fold selectivity over CB2 receptors
[35–37]. Surprisingly, when we replaced the vanillamine moiety
of PhAR with these headgroups, the aﬃnity for CB2 receptors
increased more dramatically than for CB1 receptors. Within
the generally low CB1-aﬃnity observed for these compounds,
the cyclopropylamide (12) and 2 0-choloroethanolamide (13)
of 12-phenylacetylricinoleic acid did show the highest aﬃnity
for CB1, in agreement with data with the corresponding ara-
chidonic acid amides [36]. Nevertheless, a signiﬁcantly higher
aﬃnity for CB2 receptors was observed, with a 14- and
10-fold selectivity over CB1 receptors, respectively. Even
more strikingly, the propyl- and allyl-amides (compounds 9
and 10) possessed a 40- and 80-fold selectivity over CB1
receptors, respectively. These compounds, with Ki values of
40 and 22 nM, respectively, represent an entirely new class of
high-aﬃnity CB2 ligands, developed for the ﬁrst time from a
long chain fatty acid amide lacking polyunsaturation. These
surprising ﬁndings suggest that these ﬁve headgroups cause a
switch in selectivity from CB1 to CB2 receptors when they
are acylated with a fatty acid diﬀerent from arachidonic acid,
and whose polyunsaturation is replaced by the presence of a
lipophilic aryl-containing group. Within these ﬁve amides,
however, only the cyclopropylamide (12) and, especially, the
ethanolamide (5) of 12-phenylacetylricinoleic acid retained
some of the high potency and eﬃcacy of PhAR at TRPV1
receptors, thus behaving as true dual CB2/TRPV1 ligands. In
agreement with previous structure–activity studies carried
out on TRPV1 and cannabinoid receptors, the vanillylamine
(1) and, to some extent, the catecholamine ‘‘heads’’ (2), but
not the serotonin (4) and tyramine (3) groups, yielded the most
potent and eﬃcacious compounds at TRPV1, but not CB2,
Table 1
General chemical structure of the compounds described here and their functional activity at human TRPV1 (expressed as potency, in EC50, nM, and




Compound number R1 R2 hTRPV1 hCB1 hCB2








H 90 ± 5 31 ± 2 83.2 ± 4.0 1.25 ± 0.1 >5
3
HO





H – ND 3.0 ± 1.0 >5 >5
5
HO
H 227 ± 25 105 ± 5 73.0 ± 3.5 0.9 ± 0.05 0.044 ± 0.003
6
HO
H – 126 ± 8 16.9 ± 4.5 5.0 ± 0.5 0.54 ± 0.05
7
HO
H – 63 ± 3 20.2 ± 3.5 1.75 ± 0.2 0.20 ± 0.03
8
HO
H – ND 5.2 ± 2.5 >5 0.27 ± 0.03
9 H – ND 3.3 ± 2.3 1.6 ± 0.2 0.040 ± 0.004
10 H – ND 5.4 ± 2.7 1.75 ± 0.3 0.022 ± 0.002
11 H – ND 1.3 ± 0.8 >5 0.124 ± 0.02
12 H – 63 ± 4 28.9 ± 2.3 0.31 ± 0.04 0.022 ± 0.003
13
Cl
H – ND 8.8 ± 3.7 0.36 ± 0.05 0.040 ± 0.005
(continued on next page)
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Table 1 (continued)
Compound number R1 R2 hTRPV1 hCB1 hCB2












Cl – 0.19 ± 0.03 61.8 ± 4.1 1.30 ± 0.2 0.79 ± 0.11
Aﬃnity for human TRPV1 receptors was measured by displacement binding assays against 3[H]RTX and only for the two most eﬃcacious TRPV1
agonists. Data are means ± S.D. of N = 3 experiments.























Fig. 2. Dose–response curve for the eﬀects on [Ca2+]I in HEK-293 cells overexpressing the human recombinant TRPV1 receptor, of: (1) the amides of
12-phenylacetylricinoleic acid with ethanolamine (5), dopamine (2), cyclopropylamine (12), 1 0-(R)- methyl-ethanolamine (7) and 1 0-(S)-methyl-
ethanolamine (6); (2) N-arachidonoyl-ethanolamine (anandamide); (3) N-arachidonoyldopamine (NADA) and (4) capsaicin. Data are means of
N = 3 experiments. Standard deviation bars are not shown for the sake of clarity and were never higher than 10% of the means. No signiﬁcant eﬀect
was observed with any of the substances in wild-type HEK-293 cells.
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mine (8) or 1 0(S)-methyl-ethanolamine (6) yielded weak CB2
and TRPV1 ligands, almost inactive at CB1 receptors, again
in agreement with previous studies [37]. None of the new com-
pounds could inhibit anandamide hydrolysis catalyzed by
FAAH-containing rat brain membranes, thus suggesting that
these compounds are not substrates for this enzyme and hence
more metabolically stable than the corresponding arachidonic
acid derivatives.
Although the presence of a 12-phenylacetylricinoleoyl group
instead of a C20:4 acyl group in allyl-, cyclopropyl- and hydro-
xy-ethyl amides produces an interesting shift from high CB1 to
high CB2 aﬃnity, the most potent CB2 ligands found here, i.e.
the allyl- and cyclopropylamides of PhAR (compounds 10 and
12, respectively), behaved as inverse agonists and not as ago-
nists at CB2 receptors, i.e. as inactivators rather than activa-
tors of these receptors. This property, which we could assess
only for the two most representative CB2 ligands (i.e. for one
of the compounds with, and one without, TRPV1 agonist
activity), might be shared also by the other structurally similar
CB2 ligands developed in this study, and, as suggested by re-cent studies, might result in anti-inﬂammatory actions
in vivo [13,14,38]. In fact, although anti-inﬂammatory proper-
ties have been reported more often for CB2 receptor agonists
than inverse agonists [10–12,27], it is now becoming increas-
ingly accepted that endocannabinoids, along with their widely
accepted anti-inﬂammatory eﬀects, can also exert pro-inﬂam-
matory actions (e.g. by enhancing eosinophil/neutrophil and
natural killer cell migration) depending on the pathological
condition, experimental model and pharmacological end-point
under study [39–42]. This explains why inverse agonists/antag-
onists and partial agonists (like D9-tetrahydrocannabinol) at
CB2 receptors can also exert anti-inﬂammatory actions
[13,14,38,39,42].
As mentioned above, apart from an entirely new chemical
class of CB2-selective ligands, an additional outcome of our
successful attempts at developing ‘‘hybrid’’ CB2-TRPV1 li-
gands, was the ﬁnding of at least one new compound still
exhibiting ultra-potent activity at TRPV1 receptors and, unlike
PhAR, virtually no aﬃnity for cannabinoid CB1/CB2 recep-
tors. For this compound (15), obtained from the introduction
of a para tert-butyl group in the phenylacetyl moiety of PhAR,








































































Fig. 3. Functional activity of (A) the allylamide (10) and (B) cyclopropylamide (12) of 12-phenylacetylricinoleic acid at CB2 receptors measured as
the capability of modulating GTP-c-S binding to membranes from CHO cells stably overexpressing the human recombinant CB2 receptor. In (C), a
comparison of the two compounds with the known selective CB2 antagonist/inverse agonist SR144528 is shown. Data are means ± S.E.M. of N =
5–10. Asterisks denote points that are statistically signiﬁcantly diﬀerent from zero (*P < 0.05; **P < 0.01; ***P < 0.005; ****P < 0.001; One-sample
t-test).
G. Appendino et al. / FEBS Letters 580 (2006) 568–574 573one may predict similar pharmacological applications as with
PhAR, i.e. the treatment of bladder hyper-reactivity [28], with
little side eﬀects after local infusion and with, perhaps, the
added value of further metabolic stability to enzymatic hydro-
lysis due to the sterically hindered ester function.
In conclusion, our ﬁndings exemplify how modiﬁcation of a
pleiotropic lead like PhAR can substantially remodulate its
bioactivity. PhAR was conceived as a modiﬁcation of the oral
analgesic and anti-inﬂammatory ‘‘capsaicinoid’’ olvanil [43],
inspired by the ultra-potent TRPV1 agonist resiniferatoxin
[28]. Here, by further tinkering with the structural motifs of
PhAR, it was possible to: (1) temper TRPV1 potency and im-
prove the CB2/CB1 selectivity ratio of this compound; (2) de-
velop an entirely new class of ligands with inverse agonist
properties at CB2 receptors; or (3) quench PhAR aﬃnity at
cannabinoid receptors and obtain ‘‘pure’’ TRPV1 agonists.
The ﬁrst two types of compounds are original in terms of phar-
macological proﬁle or template structure, and, apart from their
use as molecular probes to further our knowledge of the can-
nabinoid and vanilloid receptors, they also add to the growing
number of anti-inﬂammatory leads emerging from the study
on these proteins.References
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